Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myelodysplastic Syndromes 2Thrombocythemia, Essential 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Polycythemia Vera 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Hepatoblastoma 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Disease 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

Prednisone 3pembrolizumab 2Melphalan 2Cytarabine 2venetoclax 1ofatumumab 1obinutuzumab 1ioflupane 1imetelstat 1ibrutinib 1gossypol acetic acid 1gilteritinib 1fluorocholine 1fluciclovine F-18 1deltacortene 1daratumumab 1aflibercept 1abiraterone 1Temozolomide 1Self-Management 1Quality of Life 1Professional Autonomy 1Paclitaxel 1Oncolytic Virotherapy 1Octreotide 1Mitoxantrone 1Methylene Blue 1Lenalidomide 1Gemtuzumab 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Disease × imetelstat × Clear all
NCT07549451 2026-04-24

Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
30 enrolled

Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡